共 50 条
Life cycle management of critical ligand-binding reagents
被引:0
|作者:
O'Hara, Denise M.
[1
]
Theobald, Valerie
[2
]
机构:
[1] Pfizer Inc, Dept Pharmacokinet Dynam & Metab, Andover, MA 01810 USA
[2] Sanofi, Dept Clin Lab Sci, Clin Assay Dev, Cambridge, MA USA
来源:
关键词:
BIOANALYTICAL METHOD VALIDATION;
SIZE-EXCLUSION CHROMATOGRAPHY;
CELL-BASED ASSAYS;
MONOCLONAL-ANTIBODIES;
MASS-SPECTROMETRY;
SERUM SAMPLES;
THERAPEUTIC PROTEINS;
MOLECULAR TOOLS;
DRUG TOLERANCE;
IMMUNOASSAY;
D O I:
10.4155/BIO.13.241
中图分类号:
Q5 [生物化学];
学科分类号:
071010 ;
081704 ;
摘要:
Bioanalytical laboratories develop and validate ligand-binding assays (LBA) used to quantify the concentration of analytes of interest in various buffers and relevant biological matrices. The building blocks of LBA are reagents that recognize molecular and structural motifs on ligands, which are combined in various LBA formats to minimize biological matrix interferences and specifically detect and quantify the analyte of interest. The use of these LBA-requiring critical reagents, can span decades as programs mature to commercialization. Since critical reagents are generated mostly from biological systems, attention to their life cycle management, quality, characterization and sustainability are vital to the success of bioanalytical laboratories. Integrating de novo reagent generation, reagent biophysical characterization, LBA development, validation, and use, with reagent resupply processes leverages interdisciplinary activities and ensures smooth operations of a bioanalytical laboratory.
引用
收藏
页码:2679 / 2696
页数:18
相关论文